Exogenous GM3 ganglioside inhibits atherosclerosis via multiple steps: A potential atheroprotective drug

Pharmacol Res. 2019 Oct:148:104445. doi: 10.1016/j.phrs.2019.104445. Epub 2019 Sep 14.

Abstract

Atherosclerosis is one of the leading causes of morbidity and mortality worldwide. A significant increase in ganglioside GM3 content generally happens in atherosclerotic plaques causing a GM3-enriched microenvironment. It remains unclear whether the GM3-enriched microenvironment influences atherogenesis. This study sought to answer the question by investigating exogenous GM3 effects on multiple steps involved in atherogenesis. First, the physicochemical properties of native low-density lipoprotein (LDL) and LDL enriched with exogenous GM3 (GM3-LDL) were characterized by dynamic laser scattering, atomic force microscopy, and agarose gel electrophoresis. Then, electrophoretic mobility, conjugated diene and malondialdehyde production, and amino group blockage of GM3-LDL/LDL were measured to determine LDL oxidation degrees and cellular recognition/internalization of GM3-LDL/GM3-oxLDL were detected via confocal microscopy and flow cytometry. Subsequently, influences of exogenous GM3 addition on the monocyte-adhering ability of endothelial cells and on lipid deposition in macrophages were investigated. Finally, exogenous GM3 effect on atherogenesis was evaluated using apoE-/- mice fed a high-fat diet. We found that exogenous GM3 addition increased the size, charge, and stability of LDL particles, reduced LDL susceptibility to oxidation and its cellular recognition/internalization, impaired the monocyte-adhering ability of endothelial cells and lipid deposition in macrophages. Moreover, exogenous GM3 treatment also significantly decreased blood lipid levels and atherosclerotic lesion areas in atherosclerotic mice. The data imply that exogenous GM3 had an inhibitory effect on atherogenesis, suggesting a protective role of a GM3-enriched microenvironment in atherosclerotic plaques and implying a possibility of exogenous GM3 as an anti-atherosclerotic drug.

Keywords: Atherosclerosis; Atomic force microscopy (AFM); Endothelial cells; Ganglioside GM3; Low-density lipoprotein (LDL); Macrophages.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apolipoproteins E / metabolism
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / metabolism
  • Cell Line
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism
  • G(M3) Ganglioside / pharmacology*
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Lipoproteins, LDL / metabolism
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Malondialdehyde / metabolism
  • Mice
  • Monocytes / drug effects
  • Monocytes / metabolism
  • Oxidation-Reduction / drug effects
  • Plaque, Atherosclerotic / drug therapy
  • Plaque, Atherosclerotic / metabolism
  • RAW 264.7 Cells

Substances

  • Apolipoproteins E
  • G(M3) Ganglioside
  • Lipoproteins, LDL
  • oxidized low density lipoprotein
  • Malondialdehyde